By Michael Erman (Reuters) – Merck & Co said on Thursday it expects its 2022 sales to increase as much as 18 percent over last year, mostly on sales of its new COVID-19 pill, molnupiravir. The drugmaker said sales of the...
READ MORE
Biden’s Fed nominees back U.S. inflation fight
By Ann Saphir and Lindsay Dunsmuir (Reuters) – The Federal Reserve’s inflation fight should be its top priority, President Joe Biden’s nominees to the central bank’s Board of Governors told lawmakers on Thursday,...
READ MORE
Biogen’s 2022 forecast well below Street view on Alzheimer’s drug uncertainty
By Manas Mishra (Reuters) -Biogen Inc on Thursday forecast 2022 profit well below Wall Street estimates as sales of its new Alzheimer’s disease drug stall, and said it was considering deals of all sizes. The U.S. Centers for...
READ MORE
As Meta plunge slams Wall Street, retail investors ‘buy the dip’
By Noel Randewich (Reuters) – Retail investors appeared to be enthusiastically buying the dip in Wall Street’s biggest growth companies on Thursday as the U.S. stock market plunged following Facebook owner Meta Platforms...
READ MORE
Bill targeting Apple and Google approved by U.S. Senate panel
By Diane Bartz WASHINGTON (Reuters) -The Senate Judiciary Committee on Thursday voted to approve a bill that would rein in app stores of companies they said exert too much market control, particularly Apple Inc and Alphabet Inc’s...
READ MORE
Eli Lilly pushes back timeline for Alzheimer’s drug application
By Leroy Leo (Reuters) – Eli Lilly and Co deferred its timeline to complete application for accelerated approval of its experimental Alzheimer’s drug, saying it expects such an approval to make little difference with...
READ MORE